KK 220

Drug Profile

KK 220

Alternative Names: Dianexin ophthalmic - Kowa; KK-220; Recombinant human annexin A5 ophthalmic - Kowa

Latest Information Update: 25 Jun 2010

Price : $50

At a glance

  • Originator Kowa
  • Class Anti-inflammatories; Anti-ischaemics; Anticoagulants; Antithrombotics; Biological peptides; Calcium binding proteins; Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Urokinase-type plasminogen activator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Eye disorders

Most Recent Events

  • 13 Jun 2008 Phase II development is ongoing
  • 28 Feb 2006 This compound is still in active development
  • 01 Jun 2005 Phase-II clinical trials in Eye disorders in Japan (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top